Atacicept is a Vera Therapeutics Inc. program in igA Nephropathy. Its next catalyst is a Readout in Nov 2027. 1 FDA decision on record below. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
FDA approval tracked on pdufa.bio: igA Nephropathy (approved Jul 7, 2026). Earlier approvals may not be listed here; the FDA label is the full record. Sponsor: Vera Therapeutics Inc. (VERA). Market-cap tier at the time we tracked it: Mid. We track 3 catalyst events for this program: 1 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| Avoro Capital Advisors | 5,723,888 | $245.6 million | filed August 14, 2026 |
| OrbiMed Advisors | 369,596 | $15.9 million | filed August 14, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
The next tracked catalyst for Atacicept is a Readout in Nov 2027.
On Jul 7, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.
In our records Atacicept is FDA-approved for igA Nephropathy (approved Jul 7, 2026). Other approved uses may not be tracked here; the FDA label is the full record.
Vera Therapeutics Inc. (VERA).
Yes. The FDA approved an application for Atacicept on Jul 7, 2026; the decision page linked above carries the source.
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.